Insmed - INSM Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INSM shares.
View INSM analyst ratings or view top-rated stocks.

6 equities research analysts have issued twelve-month price targets for Insmed's stock. Their INSM share price forecasts range from $41.00 to $60.00. On average, they anticipate the company's share price to reach $50.86 in the next year. This suggests a possible upside of 129.0% from the stock's current price.
View analysts price targets for INSM or view top-rated stocks among Wall Street analysts.

Insmed's stock was trading at $27.24 on January 1st, 2022. Since then, INSM stock has decreased by 18.5% and is now trading at $22.21.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our INSM earnings forecast.

Insmed Incorporated (NASDAQ:INSM) announced its earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($0.80) EPS for the quarter, topping analysts' consensus estimates of ($0.89) by $0.09. The biopharmaceutical company had revenue of $65.20 million for the quarter, compared to analysts' expectations of $58.92 million. Insmed had a negative trailing twelve-month return on equity of 154.14% and a negative net margin of 188.04%. The business's quarterly revenue was up 43.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.94) EPS.

Insmed issued an update on its FY 2022 earnings guidance on Thursday, August, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $245.00M-, compared to the consensus revenue estimate of $252.26 million.

14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Insmed's stock is owned by a number of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (13.52%), Palo Alto Investors LP (4.87%), Pictet Asset Management SA (3.17%), William Blair Investment Management LLC (2.94%), Point72 Asset Management L.P. (1.38%) and Loomis Sayles & Co. L P (1.06%). Insiders that own company stock include Alfred Altomari, Christine A Pellizzari, David R Brennan, John Goll, John Soriano, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis.
View institutional ownership trends.

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INSM stock can currently be purchased for approximately $22.21.

Insmed (NASDAQ:INSM) has a market capitalization of $2.66 billion and generates $188.46 million in revenue each year. The biopharmaceutical company earns $-434,650,000.00 in net income (profit) each year or ($3.51) on an earnings per share basis.

The company employs 373 workers across the globe.

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The official website for the company is www.insmed.com. The biopharmaceutical company can be reached via phone at 908-977-9900, via email at investor.relations@insmed.com, or via fax at 732-438-0381.